Internal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukaemia has been limited by rapid generation of resistance mutations, particularly in codon Asp835 (D835). We aimed to assess the highly selective oral FLT3 inhibitor gilteritinib in patients with relapsed or refractory acute myeloid leukaemia.

中文翻译：

---

吉尔替尼对复发性或难治性急性髓性白血病的选择性抑制FLT3：一项多中心，首次在人体内，开放标签的1-2期研究。

FLT3的内部串联重复突变在急性粒细胞白血病中很常见，并且与复发快和总生存期短有关。FLT3抑制剂在急性髓性白血病患者中的临床获益已受到耐药性突变（尤其是密码子Asp835（D835））快速生成的限制。我们旨在评估复发性或难治性急性髓性白血病患者中的高选择性口服FLT3抑制剂gilteritinib。